To investigate the role of tau oligomers in nuclear lamina disruption and chromatin structure alterations in Alzheimer's Disease (AD), highlighting their potential as therapeutic targets.
Key Findings:
Nuclear lamina disruption correlates with early tau aggregation in AD patients across Braak stages I-VI, suggesting a potential biomarker for disease progression.
Pathological tau accumulation at the nuclear membrane is linked to lamina disruption in PS19 mouse brains, indicating a mechanistic pathway.
Electron microscopy revealed early nuclear invagination and chromatin decompaction in tauopathy, underscoring the cellular impact of tau oligomers.
Tau oligomers induce significant intrusions into the nuclear space, exacerbating neuronal dysfunction, which may inform therapeutic strategies.
Interpretation:
Tau oligomers are implicated in disrupting nuclear lamina integrity and altering chromatin structure, contributing to neurodegeneration in Alzheimer's Disease, with potential implications for targeted therapies.
Limitations:
Study primarily focused on specific mouse models and human brain tissue, which may not fully represent all tauopathies; future studies should explore diverse models.
Potential variability in human samples due to post-mortem interval and other confounding factors, suggesting the need for standardized protocols.
Conclusion:
The findings suggest that tau oligomers play a critical role in nuclear disruption and chromatin alterations, which may precede neuronal dysfunction in Alzheimer's Disease, highlighting their potential as therapeutic targets.
First CAR-T approach for Alzheimer’s reduces amyloid plaques in mice, while cell and gene therapies advance across blood cancers, retinal disease, amyloidosis, and FSHD
